Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science...

Frost & Sullivan Recognizes Life Technologies for Excellence in the Life
Science Research Tools Industry

MOUNTAIN VIEW, Calif., March 24 /PRNewswire/ -- Based on its recent analysis
of the drug discovery technologies market, Frost & Sullivan recognizes Life
Technologies with the 2009 North American Frost & Sullivan Company of the Year
Award. The company's size, product portfolio breadth, market segment
leadership, and strong future potential set it apart from any competitor in
the life science research tools industry. Moreover, Life Technologies shows
great commitment to providing innovative and enabling tools across the life
science research continuum.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Formed from the combination of Invitrogen and Applied Biosystems, Life
Technologies is on a clear path to become its own unique organization with
unparalleled efficiency and speed of operation. More importantly, the
reengineered Life Technologies promises extraordinary revenue growth that far
outpaces the performance of its two predecessor companies.

"Prior to the 2008 merger, Applied Biosystems held the largest percentage of
market share in the microRNA, PCR reagents, capillary electrophoresis
sequencing, qRT-PCR, and life sciences mass spectrometry markets, while
Invitrogen held the largest percentage of market share in the cell culture and
protein expression and purification markets," explains Jonathan Witonsky,
Industry Manager, Drug Discovery & Clinical Diagnostics, Frost & Sullivan. "By
merging, the new company, Life Technologies, holds a significant market share
in nine additional market segments, including the nucleic acid purification
and isolation market, the laboratory information management systems market,
the cell-based assays market, the research ELISA market, the high content
screening market, the liquid chromatography market, the protein
electrophoresis market, the RNAi market, and the proteomics array market."

Life Technologies offers approximately 50,000 products and lays claim to an
incredibly strong technological foundation of approximately 3,600 patents and
licenses. Today, with the Invitrogen and Applied Biosystems brands, Life
Technologies is at the forefront of scientific leadership not only with
exceptional products and services but also with name recognition and
visibility that is not found elsewhere in the industry. The Invitrogen brand
will remain platform agnostic with reagents that provide accurate and
consistent results on virtually any platform technology. The Applied
Biosystems brand will be workflow-centric with integrated, validated, and
certified combinations of reagents, instrumentation systems, and services.
Together, the two brands will serve the needs of a complex and fast-moving
base of approximately 75,000 customers.

Life Technologies generated revenues totaling over $3 billion in 2008. In
addition, it generated approximately $500 million in revenues from its joint
venture in the mass spectrometry systems business. The company had more than
$700 million in revenues from its cell systems business, approximately $900
million in revenues from its genetic systems business, and an estimated $1.4
billion in revenues from its molecular biology systems business. Of even
greater significance is the company's unprecedented 27 percent share of the
aggregate market segment analyses presented above.

Life Technologies has an unrivaled scale and financial strength. A $300
million investment in research and development is likely to expand the
company's position in the burgeoning markets surrounding advanced genomics,
regenerative medicine, diagnostics, forensics, and environmental testing. For
example, Life Technologies is building on its leading position in the
capillary electrophoresis sequencing market by making a major play in next
generation sequencing. By leveraging its Invitrogen brand of nucleic acid
sample preparation technologies and Applied Biosystems brand SOLiD(TM) System
for ultra-high throughput DNA sequencing, Life Technologies is expected to
have a major role in bringing next generation sequencing to the medical realm.

In the near term, Life Technologies' greatest advantage is the company's
ability to exploit its leadership position in four broad technology groups.
Specifically, Life Technologies is able to offer customers complete and
integrated workflow solutions that can be incorporated throughout a research
endeavor. The company is well-positioned to offer customers end-to-end
solutions that can bring them from early discovery to clinical application.
The world's premier scientists will be able to rely on one provider - Life
Technologies - for all of their life science research tools needs.

For the company's rapid success at bringing together Invitrogen and Applied
Biosystems, and then reengineering the combination into a whole new
organization with vast growth potential, Frost & Sullivan is pleased to
present the 2009 Company of the Year Award in the drug discovery technologies
market to Life Technologies.

Each year, Frost & Sullivan presents this award to the company that has
demonstrated excellence in terms of business development, competitive
strategy, customer satisfaction, and leadership within a particular Frost &
Sullivan Industry Research Group (IRG). This award recognizes outstanding
management, consistent growth, and the ability to offer high quality products
and/or services as well as have a positive social and economic impact on local
and national communities. It also highlights exceptional customer service
offerings and the expertise to take advantage of market changes by capturing
and solidifying market presence, or execute of innovative strategies within
the existing competitive landscape.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of
regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development. Industry analysts compare
market participants and measure performance through in-depth interviews,
analysis, and extensive secondary research in order to identify best practices
in the industry.

About Life Technologies

Life Technologies Corporation (Nasdaq: LIFE) is a global biotechnology tools
company dedicated to improving the human condition. Our systems, consumables
and services enable researchers to accelerate scientific exploration, driving
to discoveries and developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to advance
personalized medicine, regenerative science, molecular diagnostics,
agricultural and environmental research, and 21st century forensics. Life
Technologies had sales of more than $3 billion in 2008, employs approximately
9,500 people, has a presence in more than 100 countries, and possesses a
rapidly growing intellectual property estate of approximately 3,600 patents
and exclusive licenses. Life Technologies was created by the combination of
Invitrogen Corporation and Applied Biosystems Inc. For more information on how
we are making a difference please visit our website: www.lifetechnologies.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best practice models to
drive the generation, evaluation and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 31 offices on six continents. To join our Growth Partnership,
please visit http://www.frost.com.

Contact:
Jake Wengroff
210.247.3806
jake.wengroff@frost.com

SOURCE Frost & Sullivan

Jake Wengroff of Frost & Sullivan, +1-210-247-3806, jake.wengroff@frost.com